ScreenerHero

QTTB Q32 Bio Inc.

NAS · US · Healthcare · Biotechnology · q32bio.com
8.090USD+1.25%Mkt Cap: 240.83M $P/E: 2.57

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap240.83M USD
Enterprise Value140.46M USD
Revenue (TTM)53.74M USD
Gross Profit39.39M USD
Net Income (TTM)29.82M USD
Revenue/Share3.62 USD
Last Price8.090 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.57
P/E (Forward)-7.95
PEG—
EV/EBITDA6.44
EV/Revenue2.61
P/S4.49
P/B1.82
EPS (TTM)3.06
EPS (Forward)-1.02
52W Range
1.79129% of range23.57
52W High23.57 USD
52W Low1.791 USD
Profitability
Gross Margin73.30%
Oper. Margin39.94%
EBITDA Margin40.60%
Profit Margin55.49%
ROE70.98%
ROA48.27%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.54M USD
CapEx (TTM)—
FCF Margin36.09%
FCF Yield8.05%
Net Debt-100.97M USD
Net Debt/EBITDA-4.63
Balance Sheet
Debt/Equity0.37
Current Ratio20.30
Quick Ratio19.78
Book Value/Sh4.46 USD
Cash/Share3.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:18
Split DateMar 26, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.60 USD
Upside (mean)+389.5%
Target Range29.00 USD – 59.00 USD
29.00+389.5% to mean59.00
# Analysts5
Ownership
Shares Out.29.77M
Float14.64M
Insiders2.10%
Institutions80.73%
Short Interest
Short Ratio6.8d
Short % Float18.00%
Short % Out.12.67%
Shares Short3.77M
Short (prev mo.)3.14M
Technical
SMA 5013.19 (-38.7%)
SMA 2008.752 (-7.6%)
Beta-0.11
S&P 52W Chg16.45%
Avg Vol (30d)948.21K
Avg Vol (10d)1.61M
Technical Indicators
RSI (14)27.3
MACD-1.4513
MACD Signal-1.4441
MACD Hist.-0.0073
BB Upper12.14 USD
BB Middle9.573 USD
BB Lower7.007 USD
BB Width53.62%
ATR (14)0.8240 USD
Vol Ratio (20d)0.71x